Explore
New Prognostic and Predictive Markers in Cancer Progression
0 Ungluers have
Faved this Work
Login to Fave
Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 168 times via unglue.it ebook links.
- 35 - pdf (CC BY) at Unglue.it.
- 133 - pdf (CC BY) at res.mdpi.com.
Keywords
- acetyltransferase
- Akt
- antigen processing machinery (APM) molecules
- AR
- biomarker
- biomarkers
- Bladder cancer
- Blood
- BRCA1/2
- Breast cancer
- Cancer
- cancer immunotherapy
- cancer prognosis
- carcinogenesis
- cardioncology
- cardiotoxicity
- castration-resistant prostate cancer (CRPC)
- CD8+ T effector cells
- chemo-/radio resistance
- CSC
- CTCs
- Cytokines
- EMT
- eribulin
- Genetic syndromes
- genomic mutations
- Head and Neck Cancer
- head and neck neoplasms
- head and neck tumors
- HRR
- HUB nodes
- human leukocyte antigen (HLA)
- hyperglycemia
- immune checkpoint inhibitor
- K-RAS oncogene
- laryngeal cancer
- lifestyle habit
- major histocompatibility complex (MHC)
- MAPK
- medicine
- Melanoma
- melanoma resistance to MAPK/MEK inhibitors
- metabolomics
- metastasis
- microRNA
- miRNA
- MSI2
- mTOR
- musashi 2
- Mutations
- N-cadherin
- n/a
- NAA10
- new metastasis
- Nivolumab
- oncogene dependency
- oral cancer
- OSCC
- Pancreatic Cancer
- paraganglioma
- PDL1
- pheochromocytoma
- PI3K
- PI3KCA
- prediction
- prognosis
- prostate cancer
- Pten
- resistance to immune checkpoint inhibitors
- selenoproteins
- targeted therapies
- therapeutic resistance
- Therapeutic target
- TILs
- TNBC
- Transcriptomics
- tumor predisposition
- Wnt
Links
DOI: 10.3390/books978-3-03943-978-2Editions